Mira Wollner

1.2k total citations
29 papers, 836 citations indexed

About

Mira Wollner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Mira Wollner has authored 29 papers receiving a total of 836 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Mira Wollner's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (6 papers). Mira Wollner is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Lung Cancer Research Studies (6 papers). Mira Wollner collaborates with scholars based in Israel, United States and Switzerland. Mira Wollner's co-authors include Gil Bar‐Sela, Mor Moskovitz, Elizabeth Dudnik, Avivit Peer, David Meiri, Tzippy Shochat, Alona Zer, Nir Peled, Jair Bar and Abed Agbarya and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Cancer.

In The Last Decade

Mira Wollner

29 papers receiving 820 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mira Wollner Israel 14 441 334 176 167 104 29 836
Peter McArdle United Kingdom 14 518 1.2× 246 0.7× 139 0.8× 41 0.2× 159 1.5× 26 879
M. Castro Argentina 16 254 0.6× 248 0.7× 252 1.4× 26 0.2× 240 2.3× 26 1000
Michael J. Bloch United States 12 121 0.3× 145 0.4× 150 0.9× 24 0.1× 29 0.3× 63 692
Gavitt A. Woodard United States 16 199 0.5× 486 1.5× 272 1.5× 54 0.3× 22 0.2× 57 1.2k
Jing Ren China 17 160 0.4× 118 0.4× 111 0.6× 26 0.2× 42 0.4× 59 607
Vincent Geldhof Belgium 9 128 0.3× 96 0.3× 257 1.5× 11 0.1× 119 1.1× 12 1.1k
Lisa Hickey United States 13 109 0.2× 106 0.3× 113 0.6× 35 0.2× 52 0.5× 31 684
Patricia Bricmont United States 16 109 0.2× 275 0.8× 231 1.3× 45 0.3× 27 0.3× 18 665
Ralf Sigmund Germany 17 83 0.2× 1.1k 3.2× 127 0.7× 104 0.6× 56 0.5× 42 1.5k
M. Soukop United Kingdom 18 314 0.7× 147 0.4× 113 0.6× 77 0.5× 49 0.5× 53 858

Countries citing papers authored by Mira Wollner

Since Specialization
Citations

This map shows the geographic impact of Mira Wollner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mira Wollner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mira Wollner more than expected).

Fields of papers citing papers by Mira Wollner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mira Wollner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mira Wollner. The network helps show where Mira Wollner may publish in the future.

Co-authorship network of co-authors of Mira Wollner

This figure shows the co-authorship network connecting the top 25 collaborators of Mira Wollner. A scholar is included among the top collaborators of Mira Wollner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mira Wollner. Mira Wollner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rudin, Charles M., Hye Ryun Kim, Alejandro Navarro, et al.. (2023). Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.. Journal of Clinical Oncology. 41(16_suppl). 8503–8503. 10 indexed citations
2.
Bar, Jair, Nir Peled, Shiruyeh Schokrpur, et al.. (2022). Uncommon EGFR mutations on osimertinib, real-life data (UNICORN study): Updated results, brain efficacy, and resistance mechanisms.. Journal of Clinical Oncology. 40(16_suppl). 9109–9109. 2 indexed citations
3.
Shachar, Shlomit Strulov, Gil Bar‐Sela, Avivit Peer, et al.. (2022). The association between geriatric assessment, muscle measures, and treatment-related toxicity in older adults with cancer: An Israeli prospective study. Journal of Geriatric Oncology. 13(8). 1203–1207. 7 indexed citations
4.
Moskovitz, Mor, Damien Urban, Hovav Nechushtan, et al.. (2021). dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%. Clinical Lung Cancer. 23(2). 122–134. 17 indexed citations
5.
Shachar, Shlomit Strulov, Gil Bar‐Sela, Avivit Peer, et al.. (2021). The association between geriatric assessment, body composition measures, and treatment-related toxicity in elderly cancer patients: A prospective cohort study.. Journal of Clinical Oncology. 39(15_suppl). 12047–12047. 1 indexed citations
6.
Dudnik, Elizabeth, Mor Moskovitz, Abed Agbarya, et al.. (2020). Alternative nivolumab duration and scheduling in advanced nonsmall cell lung cancer: A real‐world evidence. International Journal of Cancer. 148(5). 1183–1191. 1 indexed citations
7.
Rudin, Charles M., Mark M. Awad, Alejandro Navarro, et al.. (2020). KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).. Journal of Clinical Oncology. 38(15_suppl). 9001–9001. 17 indexed citations
8.
Wollner, Mira, Sivan Shamai, Nir Peled, et al.. (2019). Immune-related Neutropenia Following Treatment With Immune Checkpoint Inhibitors. Journal of Immunotherapy. 43(2). 67–74. 14 indexed citations
9.
Dudnik, Elizabeth, Nir Peled, Hovav Nechushtan, et al.. (2018). BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. Journal of Thoracic Oncology. 13(8). 1128–1137. 155 indexed citations
10.
Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2017). OA21.02 ALK-Rearranged Non-Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism. Journal of Thoracic Oncology. 12(1). S326–S327. 1 indexed citations
11.
Turgeman, Ilit, Mira Wollner, Gamal Hassoun, Lilach Bonstein, & Gil Bar‐Sela. (2017). Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab. Anti-Cancer Drugs. 28(7). 811–814. 31 indexed citations
12.
Dudnik, Elizabeth, Mor Moskovitz, Sameh Daher, et al.. (2017). Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Lung Cancer. 126. 217–223. 80 indexed citations
13.
Zer, Alona, Mor Moskovitz, David Hwang, et al.. (2016). ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism. Clinical Lung Cancer. 18(2). 156–161. 72 indexed citations
14.
Bauer, Todd M., Martin Schüler, Rossana Berardi, et al.. (2016). MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC. Journal of Thoracic Oncology. 11(11). S257–S258. 11 indexed citations
15.
Rennert, Gad, Ran Kremer, Hedy S. Rennert, et al.. (2015). Lower lung cancer rates in Jewish smokers in Israel and the USA. International Journal of Cancer. 137(9). 2155–2162. 2 indexed citations
16.
Agbarya, Abed, Meira Melamed‐Frank, Orit Kaidar‐Person, et al.. (2014). Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib. SpringerPlus. 3(1). 507–507. 5 indexed citations
17.
18.
19.
Segal, Elena, et al.. (2012). Vitamin D deficiency in oncology patients--an ignored condition: impact on hypocalcemia and quality of life.. PubMed. 14(10). 607–12. 7 indexed citations
20.
Haim, Nissim, Edward Rosenblatt, Mira Wollner, et al.. (1992). Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatin. Cancer Chemotherapy and Pharmacology. 30(3). 243–244. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter McArdle Breakdown of academic impact, for papers by M. Castro Breakdown of academic impact, for papers by Michael J. Bloch Breakdown of academic impact, for papers by Gavitt A. Woodard Breakdown of academic impact, for papers by Jing Ren Breakdown of academic impact, for papers by Vincent Geldhof Breakdown of academic impact, for papers by Lisa Hickey Breakdown of academic impact, for papers by Patricia Bricmont Breakdown of academic impact, for papers by Ralf Sigmund Breakdown of academic impact, for papers by M. Soukop
Rankless by CCL
2026